The outcomes of severe COVID-19 pneumonia managed with supportive care in Palestine: an experience from a developing country

Abstract

Introduction: About 14% of COVID-19 patients experience severe symptoms and require hospitalization. Managing these patients could be challenging for limited-resource countries, such as Palestine. This study aimed to evaluate hospitalized severe COVID-19 patients' treatment outcomes managed with supportive care and steroids.
 Methodology: This was a single-center observational retrospective cohort study that enrolled COVID-19 patients admitted to the “Martyrs medical military complex- COVID Hospital” in Palestine. The managing physicians manually collected data through chart reviews, including patients' characteristics, complications, outcomes, and different management modalities. Continuous and categorical variables between those who were discharged alive and who died were compared using t-test and Chi-squares test, respectively.
 Results: Overall, 334 patients were included in this study. Median (IQR) age was 62(11) years, 49.1% were males, and 29.6% were ICU status patients. The median (IQR) PaO2/FiO2 ratio was 76 (67), and 67.6% of these patients had moderate to severe acute respiratory distress syndrome, and 4.8% of the patients received invasive mechanical ventilation. Most of the patients (78.7%) had at least one comorbidity, and 18.3% developed at least one complication. The overall mortality was 12.3% (95% CI 8.9-16.2%), and the median (IQR) length of hospital stay was 11 (8) days. Age (aOR 1.05, p = 0.08), smoking (aOR 4.12, p = 0.019), IMV (aOR 27.4, p < 0.001) and PaO2/FiO2 ratio (aOR 1.03, p < 0.001) were found to predict higher mortality.
 Conclusions: Supportive care for patients with severe COVID-19 pneumonia in a Palestinian hospital with limited resources was associated with in-hospital mortality of 12.3%.

Intensive Care and Organ Support Related Mortality in Patients With COVID-19: A Systematic Review and Meta-Analysis

“…After screening by abstract and title, 571 articles were selected for full-text assessment. In total, 157 studies evaluating 948,309 patients were included in the meta-analysis (9–159). The characteristics of all the included studies are shown in Table S1 (http://links.lww.com/CCX/B152).…”

The Effect of Implementation of the National Early Warning Scoring System 2 on the Outcomes of COVID-19 Hospitalized Patients

“…Liu et al found that the oxygen saturation level had a good predictive performance for predicting death. 18 Despite the lack of published statistics on NEWS2's effectiveness in controlling COVID-19 patients' clinical deterioration, this study showed that NEWS2 was good at predicting deteriorating patients based on their oxygen requirement, with an acceptable level of sensitivity and specificity for LFO, high-flow oxygen (HFO), and mechanical ventilation (intermittent mandatory ventilation [IMV]).…”

Pulmonary Hypertension in Interstitial Lung Disease: Management Options to Move Beyond Supportive Care

“…The results of the INCREASE study led to the FDA approval of inhaled treprostinil for PH-ILD in April 2021. This step made it the first FDA-approved medication specifically for PH-ILD[ 46 ].…”

“…Practically, inhaled treprostinil is administered four times daily and is titrated to a maximum tolerated dose up to 72 mcg or 12 breaths per dose [ 46 ]. Flushing, headache, diarrhea, and cough are the most common dose-limiting symptoms.…”

“…Flushing, headache, diarrhea, and cough are the most common dose-limiting symptoms. Additionally, important adverse effects related to inhaled treprostinil include symptomatic hypotension, increased bleeding risk secondary to inhibition of platelet aggregation, and bronchospasm [ 46 ]. Additionally, treprostinil is metabolized by the liver via CYP2C8, and significant drug-drug interactions are possible.…”